On July 15, 2025, Cantor Fitzgerald, under the guidance of analyst Ross Osborn, reiterated its "Overweight" rating for Organogenesis Holdings (ORGO, Financial).
The company's current price target remains unchanged at $7.00 USD, consistent with the prior assessment. This decision indicates continued confidence in ORGO's market performance and growth potential.
Organogenesis Holdings (ORGO, Financial) continues to hold an "Overweight" status, suggesting that the stock is expected to outperform the market average, as per the latest analysis from Cantor Fitzgerald.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Organogenesis Holdings Inc (ORGO, Financial) is $7.00 with a high estimate of $7.00 and a low estimate of $7.00. The average target implies an upside of 55.90% from the current price of $4.49. More detailed estimate data can be found on the Organogenesis Holdings Inc (ORGO) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Organogenesis Holdings Inc's (ORGO, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Organogenesis Holdings Inc (ORGO, Financial) in one year is $3.62, suggesting a downside of 19.38% from the current price of $4.49. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Organogenesis Holdings Inc (ORGO) Summary page.
